Atopifoam™ - non-steroidal, alcohol-free foam formulation for atopic dermatitis

Foamix and Taro Enter License Agreement for the Development and Commercialization of Foamix's PerFoam™ 1% for the Treatment of Head Lice

Globes: Foamix displays its wares

Foamix Announces New Waterless Foam Designed for Enhanced Skin Delivery - Useful for Steroids and Water Sensitive Drugs

Foamix’s Betamethasone Foam Demonstrates High Efficacy in Psoriasis Treatment and 85% Better Usability than Cream in Phase I/II Study

Foamix Names David Schuz as Senior Vice President, Intellectual Property

Foamix foam technology is featured in Ynet Health (Hebrew)

Foamix featured among finalists by AICC Eagle Star Awards for Deal of the Year

Foamix LTD is featured in Bioexecutive International, March 2006

Foamix CEO to Present “The Changing Face of Dermatology” at the Bio Business Forum at Bio International 2006 in Chicago, April 10, 2006

Foamix is featured in a news package about the thriving Israeli biotech scene, produced by FBC Media and broadcast globally on World Business

Live interview with Foamix Executive Director Dr. Stanley Hirsch on Duke and the Doctor, a radio program broadcast on 150 stations in the U.S. Dr. Hirsch discusses the benefits of foam and the Company’s plans for the future.

Foamix Receives Patents for OilGel™ In the U.S. and in Australia

Cosmeticsdesign.com: Foamix granted US patent for OilGel

LEO and Foamix to Develop Two New Medicated Foams for the Treatment of Psoriasis.

Foamix Granted Third U.S. Patent for OilGel™, In Development for Dermatological and Ophthalmic Applications.

Foamix Executive Director Dr. Stanley Hirsch to Present “Foamix - Innovative Delivery in Dermatology” at Bio-Europe 2005, November 8th at 8:30 a.m.

New Foam Product for the Treatment of Scabies: A Development Collaboration by Stiefel Laboratories, Inc. of the USA and Foamix Ltd. of Israel

Foamix Commences Phase II Study of TerbiFoam™ 2% Foam for the Treatment of Athlete’s Foot. Company Concurrently Conducts Phase II Study of Betamethasone 0.12% Emollient Foam for the Treatment of Psoriasis

Foamix to Showcase Emulsion-Based Cosmetic Foams at The Health and Beauty America (HBA) Conference in New York

Drug Topics: Are new lice treatments up to scratch?

Globes: Foamix lice treatment demonstrates 96% efficacy in Phase II/III study

Foamix’s PerFoam™ for the Treatment of Lice Demonstrates Safety and 96% Efficacy in Phase II/III Study

InPharma Technologist.com: Topical drug delivery gel patented by Foamix

Foamix Selected to Present at the Bio Business Forum at Bio International 2005 in Philadelphia in June

Israel 21C: Foam - the Israeli way to take the sting out of skin treatments

MarketWatch: Israel's Foamix eyes U.S. IPO in next 18 months

Globes article: Drug Delivery Technology co Foamix raising $5m

Foamix "Breaks the Ribbon" on New Facility

Foamix Unveils Unique Mupirocin Foam

Foamix Unveils Innovative Vaginal Foam

Frost & Sullivan alert : A new trend in dermatological drug delivery: foamy carriers

Phase II Psoriasis Study Approved

AtopiFoam™

AtopiFoam™ is a non-steroidal, alcohol-free foam formulation for atopic dermatitis.

AtopiFoam™ is a novel alcohol-free emollient foam especially designed to treat the symptoms of atopic dermatitis. It protects the injured skin from further irritation, restores skin moisture level, and exerts a potent anti-inflammatory action. A controlled study demonstrated a substantial increase in skin hydration for at least 6 hours after application of AtopiFoam™.

Product highlights:

Provides long-lasting skin hydration.
Replenishes the skin’s natural oils level.
Exerts anti-inflammatory action.
Alcohol-free.
Safe & non irritating formula.
Most suitable to treat large skin areas.
Excellent usability profile.

Partnering
Foamix has completed the development of a number of such products, which are ready for either marketing or advanced development, worldwide.

Foamix is actively seeking development and marketing partners for products from the Emollient Foam™ platform.